No association between omalizumab use and risk of cancer: a nationwide registry-based cohort study

Zarqa Ali; Alexander Egeberg; Jacob P. Thyssen; Jennifer Astrup Sørensen; Christian Vestergaard; Simon Francis Thomsen

doi:10.1111/bjd.20941

No association between omalizumab use and risk of cancer: a nationwide registry-based cohort study

Zarqa Ali, Alexander Egeberg, Jacob P. Thyssen, Jennifer Astrup Sørensen, Christian Vestergaard, Simon Francis Thomsen^*

^*Corresponding author af dette arbejde

Dermato- & Venerologisk Afd.

7 Citationer (Scopus)

Originalsprog	Engelsk
Tidsskrift	British Journal of Dermatology
Vol/bind	186
Udgave nummer	4
Sider (fra-til)	746-748
Antal sider	3
ISSN	0007-0963
DOI	https://doi.org/10.1111/bjd.20941
Status	Udgivet - 2022

Adgang til dokumentet

10.1111/bjd.20941

Andre filer og links

Link to publication in Scopus

Citationsformater

@article{ceed6b6622e94ebab18fccad83ccf4eb,

title = "No association between omalizumab use and risk of cancer: a nationwide registry-based cohort study",

author = "Zarqa Ali and Alexander Egeberg and Thyssen, {Jacob P.} and S{\o}rensen, {Jennifer Astrup} and Christian Vestergaard and Thomsen, {Simon Francis}",

note = "Funding Information: Conflicts of interest: with no relation to the current work, A.E. has received research funding from Pfizer, Eli Lilly and Company, Novartis, Bristol Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation; and honoraria as consultant and/or speaker from AbbVie, Almirall, LEO Pharma, Zuellig Pharma, Gal{\'a}pagos NV, Sun Pharmaceutical Industries Limited, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly, Novartis, Galderma, Dermavant Sciences, Inc., UCB, Mylan, Bristol Myers Squibb and Janssen. J.P.T. has attended advisory boards for Eli Lilly, Almirall, Arena Pharmaceuticals, Inc., Pfizer, AbbVie, LEO Pharma, Regeneron and Sanofi Genzyme, been an investigator for LEO Pharma, Sanofi Genzyme, Eli Lilly, AbbVie and Pfizer, and received speaker honoraria from LEO Pharma, Pfizer, Almirall, AbbVie, Eli Lilly, Regeneron and Sanofi‐Genzyme. C.V. has been a speaker, investigator and served at advisory boards for and received research grants from Novartis. S.F.T. has been a speaker, investigator, served on advisory boards and received research support from Novartis. Z.A. and J.A.S. declare they have no conflicts of interest. ",

year = "2022",

doi = "10.1111/bjd.20941",

language = "English",

volume = "186",

pages = "746--748",

journal = "British Journal of Dermatology",

issn = "0007-0963",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "4",

}

TY - JOUR

T1 - No association between omalizumab use and risk of cancer

T2 - a nationwide registry-based cohort study

AU - Ali, Zarqa

AU - Egeberg, Alexander

AU - Thyssen, Jacob P.

AU - Sørensen, Jennifer Astrup

AU - Vestergaard, Christian

AU - Thomsen, Simon Francis

N1 - Funding Information: Conflicts of interest: with no relation to the current work, A.E. has received research funding from Pfizer, Eli Lilly and Company, Novartis, Bristol Myers Squibb, AbbVie, Janssen Pharmaceuticals, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kgl Hofbundtmager Aage Bang Foundation; and honoraria as consultant and/or speaker from AbbVie, Almirall, LEO Pharma, Zuellig Pharma, Galápagos NV, Sun Pharmaceutical Industries Limited, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly, Novartis, Galderma, Dermavant Sciences, Inc., UCB, Mylan, Bristol Myers Squibb and Janssen. J.P.T. has attended advisory boards for Eli Lilly, Almirall, Arena Pharmaceuticals, Inc., Pfizer, AbbVie, LEO Pharma, Regeneron and Sanofi Genzyme, been an investigator for LEO Pharma, Sanofi Genzyme, Eli Lilly, AbbVie and Pfizer, and received speaker honoraria from LEO Pharma, Pfizer, Almirall, AbbVie, Eli Lilly, Regeneron and Sanofi‐Genzyme. C.V. has been a speaker, investigator and served at advisory boards for and received research grants from Novartis. S.F.T. has been a speaker, investigator, served on advisory boards and received research support from Novartis. Z.A. and J.A.S. declare they have no conflicts of interest.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85123482479&partnerID=8YFLogxK

U2 - 10.1111/bjd.20941

DO - 10.1111/bjd.20941

M3 - Letter

C2 - 34878656

AN - SCOPUS:85123482479

SN - 0007-0963

VL - 186

SP - 746

EP - 748

JO - British Journal of Dermatology

JF - British Journal of Dermatology

IS - 4

ER -